Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04728893 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
A Phase 2 study of Non-Hodgkin's Lymphoma and Hematologic Malignancies, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 490
- Enrollment target
- 20
- Study locations
NCT04728893 is a Phase 2 study of Non-Hodgkin's Lymphoma and Hematologic Malignancies that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 490 participants, above the 214-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (129% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT04728893, a Phase 2 study of Non-Hodgkin's Lymphoma and Hematologic Malignancies, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 490 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Conditions Studied
Interventions
- DRUG Nemtabrutinib
Study Locations (20)
Other
- FUNDALEU ( Site 0104) - Caba
- Hospital Privado Universitario de Córdoba ( Site 0107) - Córdoba
- Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110) - Mendoza
California
- University of California San Diego Moores Cancer Center ( Site 2717) - La Jolla
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724) - Torrance
New Jersey
- Astera Cancer Care ( Site 2732) - East Brunswick
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704) - Hackensack
Arkansas
- Highlands Oncology Group ( Site 2728) - Springdale
Colorado
- Colorado Blood Cancer Institute ( Site 2726) - Denver
Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 2729) - Louisville
Minnesota
- Mayo Clinic - Rochester ( Site 2706) - Rochester
North Dakota
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708) - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2021-04-05 |
| Est. Completion | 2029-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04728893
The ClinicalTrials.gov registry entry for NCT04728893 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 214-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (129% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Nemtabrutinib is the first listed.
NCT04728893 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04728893 about?
NCT04728893 is a clinical study titled "Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)". The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MC...
What is the current status of trial NCT04728893?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 490 participants. The study started on 2021-04-05. Estimated completion is 2029-01-04.
What conditions does trial NCT04728893 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Hematologic Malignancies, Chronic Lymphocytic Leukaemia, Waldenstroms Macroglobulinaemia.
What interventions are being tested in trial NCT04728893?
The interventions under investigation include: Nemtabrutinib (DRUG).
Who is sponsoring clinical trial NCT04728893?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04728893 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.